In the present study, we took advantage of an ex vivo system to compare the cardiac effects of different DPP-4 inhibitors, observing that linagliptin consistently improved the recovery of contractile function after ischemia reperfusion injury. This evidence concerns the gene DPP4 and ischemia reperfusion injury.